Checkpoint machinery protects against cancer

Connections between DNA-PK, ATM, ATR and mTOR dependent pathways

What is the potential of TOR inhibition for cancer therapy?

Mathematical modelling can be used in cancer therapy

Recombination can drive tumourogenesis

The role of the PI3K and TOR pathways in cancer

Utilising disease heterogeneity and emerging biomarkers to individualise prostate treatment

Integrated genomic correlates of response to PD-1 inhibitor nivolumab in mRCC

Comparing adjuvant radiotherapy plus chemo vs. adjuvant chemo following cystectomy for bladder cancer

Molecular genetics of testicular cancer: What does the clinician need to know?

Actionable targets in patients with cisplatin-resistant advanced germ cell tumours

Global cancer partnership